openPR Logo
Press release

OTC Cough, Cold and Allergy Medicine Market is Expected to Accelerate at a Whopping 5.5% CAGR by 2032

11-11-2022 08:24 AM CET | Health & Medicine

Press release from: Fact.MR

/ PR Agency: Fact.MR
According to Fact MR's recent market research, sales of OTC Cough, Cold, and Allergy Medicine to swell at propelled CAGR through 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.

Focus on improving overall patient care will remain a chief growth driver. Besides this, OTC Cough, Cold, and Allergy Medicine market will continue gaining from increasing willingness among patients and families to spend on advanced healthcare.

To remain 'ahead' of your competitors, request for a sample -
https://www.factmr.com/connectus/sample?flag=S&rep_id=71

To offer an in-depth overview, the report provides sales projections for over 20 countries. It also identifies segments exhibiting maximum growth.

Key Takeaways from Market Study

• Global OTC cough, cold, and allergy medicine market to top US$ 60 Bn by 2031.
• Bronchodialators projected to reach valuation of around US$ 25 Bn by 2031.
• Antihistamine projected to record above 4% CAGR over next 10 years.
• Market in APEJ holds share of more than 40%.
• Market in South Korea expected to reach valuation of US$ 15 Bn by 2031.
• Market in Australia to record 3% CAGR over forecast period of 2021- 2031.

"Increasing investments by public and government bodies in the healthcare sector, higher availability of a wide range of products, and easy access to self-administered drugs for minor allergies and illnesses are positively impacting sales of OTC cough, cold, and allergy medicines," says a Fact.MR analyst.

Key players in OTC cough, cold, and allergy medicine market

• Sanofi-Aventis
• Johnson & Johnson Service Inc.
• Reckitt Benckiser Group Plc.
• Novartis AG
• GlaxoSmithKline Plc.
• AstraZeneca Plc.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Prestige Brands Holdings Inc.
• Procter & Gamble Co.
• Bristol-Myers Squib Co.
• Merck & Co.
• Allergen

Connect to an Expert-
https://www.factmr.com/connectus/sample?flag=AE&rep_id=71

Competitive Landscape

The market is hugely competitive with a number of top OTC cough, cold, and allergy medicine manufacturers. Few major players currently dominate the market in terms of revenue share.
Personalized patient care and access to complete end-to-end medical device products and services are now available from healthcare service providers and top companies in the OTC cough, cold & allergy medicine market.

Report Benefits & Key Questions Answered

• OTC Cough, Cold, and Allergy Medicine Category and segment level analysis: Fact MR provides a detailed analysis of the factors influencing sales growth across key segments. It highlights key growth drivers and provides useful information for identifying sales prospects at the regional and local level.
• OTC Cough, Cold, and Allergy Medicine Historical volume analysis: The report provides a comparison of OTC Cough, Cold, and Allergy Medicine's historical sales and projected sales performance for 2021-2031.
• OTC Cough, Cold, and Allergy Medicine Manufacturing trend analysis: The report offers a detailed analysis of manufacturing trends in the OTC Cough, Cold, and Allergy Medicine market. It carefully gauges the impact of changing healthcare needs of key demographics globally
• OTC Cough, Cold, and Allergy Medicine Consumption by demographics: The report investigates consumer behavior affecting OTC Cough, Cold, and Allergy Medicine demand outlook for the assessment period. Effect of their keenness for digital trends on OTC Cough, Cold, and Allergy Medicine market is carefully analyzed
• Post COVID consumer spending on OTC Cough, Cold, and Allergy Medicine: Healthcare industry has been largely influenced by COVID-19 pandemic. The Fact MR Market survey analyzed consumer spending post COVID-19. It assesses how current trends that will influence expenditure on healthcare services, thus affecting OTC Cough, Cold, and Allergy Medicine market growth.

Get Full Access of this Report through our PayPal Payment Gateway
https://www.factmr.com/checkout/71

Key Segments Covered in the OTC Cough, Cold and Allergy Medicine Industry Survey

• By Drug Type :
o OTC Antihistamine
o OTC Expectorants
o OTC Bronchodilators
o OTC Antibiotics

• By OTC Channel :
o Pharmacies
o Drug Store
o Modern Trade
o Online

• By Dosage :
o Capsules
o Liquid
o Tablets
o Lozenges
o Others
 OTC Liquid Cough, Cold & Allergy Solutions
 OTC Liquid Cough, Cold & Allergy Drops
 OTC Liquid Cough, Cold & Allergy Granules
 OTC Liquid Cough, Cold & Allergy Syrup
 OTC Liquid Cough, Cold & Allergy Pills

• By Application :
o Babies
o Adults
o School-age Children

• By Region :
o North America
o Latin America
o Europe
o East Asia
o South Asia
o Oceania
o Middle East Africa

For more insights:

Dental Laboratories Market: https://www.newswire.co.kr/newsRead.php?no=947698

Bleeding Disorders Treatment Market: https://www.newswire.co.kr/newsRead.php?no=948105

21st floor , 136 Sejong-daero,
Seoul,100-768
South Korea

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OTC Cough, Cold and Allergy Medicine Market is Expected to Accelerate at a Whopping 5.5% CAGR by 2032 here

News-ID: 2803082 • Views:

More Releases from Fact.MR

Insulated Drinkware Market to Hit USD 2.57 Billion by 2033 | YETI, Thermos L.L.C., Hydro Flask Lead - Fact.MR
Insulated Drinkware Market to Hit USD 2.57 Billion by 2033 | YETI, Thermos L.L.C …
The global insulated drinkware market was valued at US$ 1.39 billion in 2023 and is forecasted to expand at a 6.3% CAGR over the next ten years. Worldwide sales of insulated drinkware are projected to reach US$ 2.57 billion by 2033-end.This robust growth is driven by increasing consumer awareness of sustainability, rising participation in outdoor activities, and the growing demand for reusable, eco-friendly products amid bans on single-use plastics. The market
Digital Twin Market is Growing at a CAGR of 34.3% d by 2033 | Key Players: ABB Ltd, ANSYS, Inc, AT&T Inc, AVEVA Group plc, Bentley Systems
Digital Twin Market is Growing at a CAGR of 34.3% d by 2033 | Key Players: ABB L …
Digital Twin Market is valued at USD 5 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 34.3%, reaching USD 95 billion by 2033. This explosive growth is driven by the increasing adoption of digital twins across industries to optimize operations, reduce costs, and enhance decision-making through virtual replicas of physical assets. Digital twins integrate IoT, AI, and data analytics to simulate real-world
Hemato Oncology Testing Market is Forecasted to Reach USD 23.64 Billion by 2033 | Fact.MR Report
09-02-2025 | Health & Medicine
Fact.MR
Hemato Oncology Testing Market is Forecasted to Reach USD 23.64 Billion by 2033 …
The global hemato oncology testing market is valued at USD 4.33 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 18.5%, reaching USD 23.64 billion by 2033. This rapid growth is driven by the increasing prevalence of blood-related cancers, such as lymphoma and leukemia, and advancements in diagnostic technologies like next-generation sequencing (NGS) and polymerase chain reaction (PCR). Hemato oncology testing plays a
Osseointegration Implants Market is Anticipated to Reach USD 6.85 Billion by 2035
09-02-2025 | Health & Medicine
Fact.MR
Osseointegration Implants Market is Anticipated to Reach USD 6.85 Billion by 203 …
Osseointegration Implants Market is poised for robust growth, with its valuation projected to rise from USD 3.17 billion in 2025 to USD 6.85 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8%. This expansion is driven by the increasing prevalence of orthopedic and dental disorders, such as osteoarthritis, rheumatoid arthritis, and edentulism, which necessitate advanced implant solutions. Osseointegration implants, which fuse directly with bone to provide stable

All 5 Releases


More Releases for OTC

Lawsuit filed for Investors who lost money with shares of adidas AG (OTC: ADDYY, …
An investor, who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), filed a lawsuit over alleged violations of Federal Securities Laws by adidas AG in connection with certain allegedly false and misleading statements. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 27, 2023. adidas AG (OTC: ADDYY, OTC: ADDDF) investors should contact
Investigation for Investors in adidas AG (OTC: ADDYY, OTC: ADDDF) announced over …
An investigation on behalf of investors in shares of adidas AG (OTC: ADDYY, OTC: ADDDF) was announced over potential breaches of fiduciary duties by certain officers and directors at adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain adidas AG officers and
AMERICAN HEMP VENTURES INC (OTC: AMHV) TO BECOME YOUNEEQAI TECHNICAL SERVICES In …
FOR IMMEDIATE RELEASE Denver Colorado, March 31, 2023, American Hemp Ventures, Inc. (OTC: AMHV) announced today that its name has changed effective immediately to YouneeqAI Technical Services inc. (OTC: YQAI) reflecting the Company's new focus into cookie-less AI technology services. The current management team has over 50 years of experience in technology services and innovation. Murray Galbraith, YQAI's CEO, is the Founder of YouneeqAI's software solution and has operated several private technology
Investigation announced for Investors who lost money with shares of adidas AG (O …
An investigation was announced for investors of adidas AG (OTC: ADDYY, OTC: ADDDF) shares over potential securities laws violations by adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of adidas AG (OTC: ADDYY,
Fuel Cell Market Technological Trends and Business Opportunities 2021 To 2026; P …
MarketInsightsReports has published a report titled global Fuel Cell Market research report 2021 that is a detailed observation of several aspects, including the rate of growth, technological advances, and different methodologies implemented by the primary current market players. The report is based on a collective analysis of data, which is obtained through primary and secondary research. It provides a systematic approach to the current and prospective scenario of this market. The
Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to